Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial | Zendy

Alejandro ArenasPinto | Zendy; Wolfgang Stöhr | Zendy; Hans Rolf Jäger | Zendy; Lewis Haddow | Zendy; Amanda Clarke | Zendy; Margaret Johnson | Zendy; Fabian Chen | Zendy; Alan Winston | Zendy; Claudia Godi | Zendy; Stefanie Thust | Zendy; Rita Trombin | Zendy; Janet Cairns | Zendy; Bhavana Solanky | Zendy; Xavier Golay | Zendy; Nicholas I. Paton | Zendy

Open Access

Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial

Author(s) -

Alejandro ArenasPinto,

Wolfgang Stöhr,

Hans Rolf Jäger,

Lewis Haddow,

Amanda Clarke,

Margaret Johnson,

Fabian Chen,

Alan Winston,

Claudia Godi,

Stefanie Thust,

Rita Trombin,

Janet Cairns,

Bhavana Solanky,

Xavier Golay,

Nicholas I. Paton

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw279

Subject(s) - medicine , ritonavir , protease inhibitor (pharmacology) , neurocognitive , neuroimaging , randomized controlled trial , antiretroviral therapy , human immunodeficiency virus (hiv) , viral load , virology , pharmacology , psychiatry , cognition

To determine whether treatment with ritonavir-boosted protease inhibitor (PI) monotherapy is associated with detrimental effects on neurocognitive function or brain imaging markers compared to standard antiretroviral therapy (ART).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research